IBI351 Receives Breakthrough Therapy Designation in China for Previously Treated Advanced CRC
China’s National Medical Products Administration has granted a breakthrough therapy designation to the KRAS G12C inhibitor IBI351 as monotherapy for previously treated patients with advanced colorectal carcinoma harboring a KRAS G12C mutation.
Source: onclive.com